2025-09-19 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX) based on the data you provided, presented in English with numerical data first, followed by analysis:

## RXRX Analysis:

**0. Overview:**

*   Ticker: RXRX
*   Company: Recursion Pharmaceuticals Inc
*   Description: Recursion Pharmaceuticals accelerates drug discovery through advanced technology and machine learning.

**1. Performance vs. S&P 500 (VOO):**

*   RXRX Cumulative Return: -45.74%
*   VOO Cumulative Return: 45.10%
*   Absolute Divergence: -90.4
*   Relative Divergence: 0.0

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the period analyzed. The cumulative return difference is substantial (-90.4%). The relative divergence of 0.0 indicates that RXRX is at the very bottom of its historical divergence range compared to VOO.

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha   | Beta  | Cap(B) |
| :--------- | :----- | :----- | :------ | :---- | :----- |
| 2021-2023  | 5.0%   | 73.6%  | -1.0%   | -0.1  | 4.3    |
| 2022-2024  | 0.0%   | 73.6%  | -25.0%  | 0.1   | 3.0    |
| 2023-2025  | 6.0%   | 73.6%  | -52.0%  | 0.1   | 2.1    |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate fluctuates.
*   **MDD:** The Maximum Drawdown is consistently high at 73.6%, indicating significant volatility and potential risk.
*   **Alpha:**  Alpha is significantly negative and decreasing, indicating substantial underperformance relative to the market.
*   **Beta:** Beta is low and fluctuates near zero, suggesting that RXRX's price is not strongly correlated with the overall market.
*   **Cap(B):** Market capitalization has decreased over time.

**2. Recent Stock Price Movement:**

*   Current Price: 4.93
*   Previous Close: 4.71
*   Change: 4.67%
*   5-Day Moving Average: 4.816
*   20-Day Moving Average: 4.7497
*   60-Day Moving Average: 5.2995

**Analysis:** The stock price experienced a significant positive change (4.67%) in the last market session, with a current price of $4.93. The price is above the 5-day and 20-day moving averages, but still below the 60-day moving average. This suggests a recent upward trend, but longer-term trends may still be negative. The substantial change suggests potential volatility or news-driven movement.

**3. Technical Indicators:**

*   Market Risk Indicator (MRI): 0.3324 (Low Risk)
*   RSI: 52.11699037793922
*   PPO: 0.9908
*   Hybrid Signal: cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   Delta_Previous_Relative_Divergence (20-day): -1.2 (Decreasing)
*   Expected Return: -2719.9%

**Analysis:**

*   The Market Risk Indicator is in the "Low Risk" range.
*   The RSI is near neutral, suggesting neither overbought nor oversold conditions.
*   The PPO (Percentage Price Oscillator) is positive, suggesting a possible upward trend in momentum.
*   The Hybrid Signal recommends a cautious buy.
*   The negative change in relative divergence (-1.2) indicates short-term underperformance compared to the benchmark.
*   The Expected Return is extremely negative, suggesting substantial underperformance against the S&P 500 over a long-term investment horizon.

**4. Recent News & Significant Events:**

*   **[2025-09-15] RXRX Stock Sinks As Market Gains:**  Indicates recent negative price action *despite* positive market trends.
*   **[2025-09-15] Needham Retains Buy Rating:** A positive signal from an analyst, maintaining a price target of $8.
*   **[2025-09-12] Insider Sold Shares:**  This is generally a negative signal, suggesting insiders may believe the stock is overvalued or have better uses for their capital.
*   **[2025-09-03] Rallybio Receives Equity Milestone:**  Potentially positive for Recursion as it signifies progress in a partnered project.
*   **[2025-08-29] If You'd Invested $1,000 in RXRX 4 Years Ago:** This is a retrospective analysis, potentially highlighting past performance issues.
*   **[2025-08-28] RXRX Expands Rare Disease Pipeline:** This is a positive development, suggesting growth and diversification.

**Analysis:** The news is mixed. While the expansion of the rare disease pipeline and Needham's buy rating are positive, the insider selling and underperformance relative to the market are concerning.

**4-2. Analyst Opinions:**

*   Consensus: Hold (2.62)
*   Opinions: 6
*   Target Price (avg/high/low): 6.47 / 10.00 / 3.00
*   Recent Rating Changes: No recent changes indicated.

**Analysis:** The analyst consensus is "Hold," suggesting a neutral outlook. The average target price ($6.47) is higher than the current price, indicating potential upside, but the low target ($3.00) suggests significant risk.

**5. Recent Earnings Analysis:**

| 날짜       | EPS    | 매출     |
| :--------- | :----- | :------- |
| 2025-08-05 | -0.41  | 0.02 B$  |
| 2025-05-05 | -0.5   | 0.01 B$  |
| 2024-11-06 | -0.34  | 0.03 B$  |
| 2024-08-08 | -0.4   | 0.01 B$  |
| 2025-08-05 | -0.4   | 0.01 B$  |

**Analysis:** RXRX consistently reports negative Earnings Per Share (EPS), and revenue fluctuates. The lack of profitability is a concern.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
| :--------- | :------ | :------------ |
| 2025-06-30 | $0.02B  | -5.54%       |
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE       |
| :--------- | :------ | :-------- |
| 2025-06-30 | $0.92B  | -18.70%   |
| 2025-03-31 | $0.93B  | -21.68%   |
| 2024-12-31 | $1.03B  | -17.29%   |
| 2024-09-30 | $0.52B  | -18.27%   |
| 2024-06-30 | $0.58B  | -16.69%   |

**Analysis:** Revenue is inconsistent, and profit margins are generally negative, with some positive quarters. Equity fluctuates, and Return on Equity (ROE) is consistently negative, confirming the lack of profitability.

**7. Overall Assessment:**

RXRX exhibits a mixed picture. While the company is involved in innovative drug discovery and has expanded its pipeline, several factors raise concerns:

*   **Significant Underperformance:** The stock has significantly underperformed the S&P 500.
*   **High Volatility:** Indicated by the high Maximum Drawdown.
*   **Consistent Losses:** Negative EPS, negative profit margins, and negative ROE highlight a lack of profitability.
*   **Insider Selling:** This raises concerns about management's confidence in the company's prospects.
*   **Mixed News:** Positive news about pipeline expansion is offset by negative news about stock underperformance.

**In conclusion, RXRX is a high-risk investment. While analyst target prices suggest potential upside, the company's consistent losses, high volatility, and underperformance relative to the market warrant caution.** A thorough understanding of the company's financials, drug development pipeline, and competitive landscape is essential before considering an investment.
